Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1972 4
1975 2
1976 4
1977 4
1978 11
1979 25
1980 13
1981 11
1982 16
1983 5
1984 10
1985 14
1986 31
1987 32
1988 25
1989 21
1990 12
1991 6
1992 5
1993 4
1994 6
1995 7
1996 7
1997 9
1998 9
1999 5
2000 6
2001 5
2002 2
2003 3
2004 4
2005 2
2006 2
2007 4
2008 1
2009 3
2010 2
2011 3
2012 3
2013 6
2014 5
2015 8
2016 10
2017 13
2018 8
2019 8
2020 9
2021 13
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Results by year

Filters applied: . Clear all
Page 1
RNA-Targeted Therapeutics.
Crooke ST, Witztum JL, Bennett CF, Baker BF. Crooke ST, et al. Cell Metab. 2018 Apr 3;27(4):714-739. doi: 10.1016/j.cmet.2018.03.004. Cell Metab. 2018. PMID: 29617640 Free article. Review.
Antisense technology: an overview and prospectus.
Crooke ST, Baker BF, Crooke RM, Liang XH. Crooke ST, et al. Nat Rev Drug Discov. 2021 Jun;20(6):427-453. doi: 10.1038/s41573-021-00162-z. Epub 2021 Mar 24. Nat Rev Drug Discov. 2021. PMID: 33762737 Review.
Antisense technology: A review.
Crooke ST, Liang XH, Baker BF, Crooke RM. Crooke ST, et al. J Biol Chem. 2021 Jan-Jun;296:100416. doi: 10.1016/j.jbc.2021.100416. Epub 2021 Feb 16. J Biol Chem. 2021. PMID: 33600796 Free PMC article. Review.
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Shen W, et al. Among authors: crooke st. Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29. Nat Biotechnol. 2019. PMID: 31036929
Maytansine.
Issell BF, Crooke ST. Issell BF, et al. Among authors: crooke st. Cancer Treat Rev. 1978 Dec;5(4):199-207. doi: 10.1016/s0305-7372(78)80014-0. Cancer Treat Rev. 1978. PMID: 367597 Review. No abstract available.
RNA-Targeted Therapeutics.
Crooke ST, Witztum JL, Bennett CF, Baker BF. Crooke ST, et al. Cell Metab. 2019 Feb 5;29(2):501. doi: 10.1016/j.cmet.2019.01.001. Cell Metab. 2019. PMID: 30726759 Free article. No abstract available.
Antisense technology.
Crooke ST. Crooke ST. Curr Opin Biotechnol. 1991 Apr;2(2):282-7. doi: 10.1016/0958-1669(91)90022-w. Curr Opin Biotechnol. 1991. PMID: 1367866 Review.
Oligonucleotide therapy.
Crooke ST. Crooke ST. Curr Opin Biotechnol. 1992 Dec;3(6):656-61. doi: 10.1016/0958-1669(92)90012-8. Curr Opin Biotechnol. 1992. PMID: 1369122 Review.
Etoposide (VP-16-213).
Issell BF, Crooke ST. Issell BF, et al. Among authors: crooke st. Cancer Treat Rev. 1979 Jun;6(2):107-24. doi: 10.1016/s0305-7372(79)80045-6. Cancer Treat Rev. 1979. PMID: 385138 Review. No abstract available.
Antisense therapeutics.
Crooke ST. Crooke ST. Biotechnol Genet Eng Rev. 1998;15:121-57. doi: 10.1080/02648725.1998.10647954. Biotechnol Genet Eng Rev. 1998. PMID: 9573607 Review. No abstract available.
423 results